Wallets linked to the $6.3 billion Binance hack are converting stolen SOL tokens into Bitcoin through a multi-step route involving USDC, Ethereum (ETH), and THORChain. The stolen SOL is first sold for USDC, which is then used on Ethereum to buy ETH, and finally swapped for BTC via THORChain. This complex conversion route helps obscure the origin of the funds by changing assets multiple times before reaching Bitcoin, the final destination. The process is ongoing, highlighting continued efforts to launder the stolen assets through decentralized finance protocols.
The story about SOL token movements through USDC and ETH before THORChain BTC conversion is provided here with Pluang market context as of Nov 04, 2026 23:32 WIB. Of 50 major cryptocurrencies priced on Pluang, 47 rose and 2 fell today. Notable movers include VET (VeChain) at Rp108 with a 1-day change of +5.23% and Pluang order activity showing 99% Buy, GRT (The Graph) at Rp378 with +5.16%, and LINK (Chainlink) at Rp210.973 with +4.80%.
Goldman Sachs Group, Inc. disclosed that it briefly held a combined stake exceeding 3% in Ontex Group NV shares as of October 27, 2026, with 566,115 voting rights and 1,965,157 financial instruments. However, by October 28, 2026, their combined posit...
BNP Paribas announced its monthly declaration of voting rights and shares as of October 31, 2026. The bank reported a total of 1,101,600,607 shares and an equal number of voting rights. This update is part of regulatory compliance under French commer...
Ontex disclosed that Goldman Sachs Group, Inc. crossed the 3% ownership threshold in Ontex shares on October 27, 2026, holding a combined total of 3.07% including voting rights and financial instruments. However, the next day, October 28, 2026, Goldm...
Neion Bio has appointed John A. Maga, Ph.D., as Head of Biologics and CMC to lead the development of biologic medicines using its Raptor platform, which produces proteins in transgenic chicken eggs. Maga brings over 25 years of biopharmaceutical expe...
The National Advertising Division (NAD) recommended that Good Life Meds discontinue claims about health benefits and personalization for its compounded Tirzepatide+ weight loss products after a challenge by Eli Lilly. NAD found that Good Life lacked ...
